Linezolid Sandoz (Linezolid)

Linezolid is an oxazolidinone antibiotic indicated for several serious Gram‑positive bacterial infections.

• Methicillin‑resistant Staphylococcus aureus (MRSA) infections: effective in skin, soft‑tissue infections and pneumonia caused by MRSA.
• Vancomycin‑resistant Enterococcus (VRE) infections: used to treat infections where vancomycin resistance limits options.
• Community‑acquired and hospital‑acquired pneumonia: provides coverage against susceptible Gram‑positive pathogens, including resistant strains.
• Complicated skin and soft‑tissue infections (cSSTI): achieves clinical cure in infections caused by susceptible Gram‑positive organisms, including resistant strains.
• Bone and joint infections: used as part of therapy for osteomyelitis caused by susceptible Gram‑positive bacteria when other options are limited.

• Linezolid exerts its antibacterial activity by binding to the 23S rRNA of the 50S ribosomal subunit. This interaction prevents the formation of the initiation complex required for protein synthesis, thereby inhibiting bacterial growth. The binding is reversible and selective for bacterial ribosomes, resulting in a bacteriostatic effect against most susceptible Gram‑positive organisms. Because it targets a site distinct from those of β‑lactams and glycopeptides, linezolid retains activity against strains resistant to those classes.

Linezolid may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects

• Nausea: mild gastrointestinal upset.
• Diarrhea: loose stools.
• Headache: transient cranial discomfort.
• Rash: mild skin erythema.

Serious or Rare Side Effects

• Myelosuppression: thrombocytopenia or anemia.
• Peripheral neuropathy: sensory changes.
• Serotonin syndrome: when combined with serotonergic drugs.

When prescribing linezolid, several precautions should be observed to minimize risks and ensure safe use.

• Renal impairment: adjust monitoring as accumulation may occur.
• Hepatic dysfunction: evaluate liver function before and during therapy.
• Concomitant serotonergic drugs: avoid due to risk of serotonin syndrome.
• Long‑term therapy (>2 weeks): monitor blood counts for myelosuppression.
• Pregnancy and lactation: assess risk‑benefit as safety data are limited.
• Store at ambient temperature: keep below 25 °C in original packaging, protect from moisture.

Linezolid interacts with several medicines; awareness of the interaction level guides clinical decisions.

Major Interactions (Avoid)

• Selective serotonin reuptake inhibitors (SSRIs) and other serotonergic agents: may precipitate serotonin syndrome.
• Monoamine oxidase inhibitors (MAOIs): increased risk of hypertensive crisis.
• Rifampicin: may reduce linezolid plasma concentrations.

Moderate Interactions (Monitor Closely)

• Warfarin: potential increase in INR, monitor coagulation.
• Cytochrome P450 substrates (e.g., phenytoin): possible altered metabolism.
• Tyramine‑rich foods: may cause hypertensive episodes when combined with MAOIs.